Reading the tape
NASDAQ: GYRE
Gyre Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$775.95M
52w High
$11.78
52w Low
$6.57
P/E
145.07
Volume
1.27K
Outstanding Shares
96.99M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -10.1%Revenue (TTM): 10.24%FCF (TTM): 86.78%P/E: 90th pct
What changed
The stock fell 10.1% over the last year. Revenue grew 10.24% over the trailing twelve months. Operating margin moved from 15.28% to 9.85%. Free cash flow grew 86.78% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 9.85%. A decisive move in revenue — currently up 10.24% — would be the clearest signal to resolve the ambiguity.
Company profile
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
CEOPing Zhang
SectorHealthcare
IndustryBiotechnology
Employees579
IPO dateApr 12, 2006
Valuation
Forward P/E—
EV/EBITDA42.44
Enterprise value$594.64M
Stock splits
Oct 31, 2023↓ Reverse
Every 15 shares became 1
Feb 13, 2017↓ Reverse
Every 15 shares became 1
Aug 21, 2015↓ Reverse
Every 7 shares became 1
Profitability & growth
Revenue growth33.45%
Gross margin95.35%▼1.01%vs FY2024
Operating margin9.85%▼35.53%vs FY2024
ROE4.74%▼75.16%vs FY2024
Analyst consensus
RatingBuy
Target price$17.00▲112.50%
1
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.06 · Revenue est $31.61M
View